An Open-Label, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Subcutaneous Dose of BCD-089 in Healthy Volunteers

Trial Profile

An Open-Label, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Subcutaneous Dose of BCD-089 in Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Jul 2017

At a glance

  • Drugs BCD 089 (Primary)
  • Indications Autoimmune disorders
  • Focus First in man; Pharmacokinetics
  • Sponsors Biocad
  • Most Recent Events

    • 14 Jul 2017 Status changed from active, no longer recruiting to completed.
    • 10 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top